Imaging3, Inc. “State of the Company” Conference Call Summarizes Progress of Initiatives

BURBANK, CA--(Marketwire - September 24, 2009) -

Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, conducted a “State of the Company” conference call on Wednesday, September 23, 2009 at 12:00 Pacific Daylight Time. During the call, CEO Dean Janes announced that the next submission to the FDA will take place on Wednesday, September 30, 2009. The announcement was followed by a question and answer session in which Mr. Janes took questions. The audio recording is available to listen by calling the following telephone numbers:

Toll Free within the US: 888-203-1112 International Toll Call: +1 719-457-0820 Passcode: 61836841 

The conference call will also be available on the company’s website, www.imaging3.com, within 24 hours.

About Imaging3

Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.